TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 avr. 2022 17h00 HE
|
TELA Bio, Inc.
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio to Announce First Quarter 2022 Financial Results
26 avr. 2022 07h00 HE
|
TELA Bio, Inc.
MALVERN, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Appoints D. Taylor Ocasio as General Counsel
18 avr. 2022 07h00 HE
|
TELA Bio, Inc.
MALVERN, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio to Participate in Upcoming Needham & Co. 21st Annual Healthcare Virtual Conference
30 mars 2022 07h00 HE
|
TELA Bio, Inc.
MALVERN, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results
21 mars 2022 16h01 HE
|
TELA Bio, Inc.
MALVERN, Pa., March 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio to Participate in Upcoming Canaccord Genuity Musculoskeletal Conference in Chicago, IL
16 mars 2022 07h00 HE
|
TELA Bio, Inc.
MALVERN, Pa., March 16, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio to Announce Fourth Quarter and Full Year 2021 Financial Results
07 mars 2022 16h01 HE
|
TELA Bio, Inc.
MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution
03 mars 2022 07h00 HE
|
TELA Bio, Inc.
MALVERN, Pa., March 03, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 févr. 2022 16h01 HE
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 25, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand
10 nov. 2021 16h01 HE
|
TELA Bio, Inc.
MALVERN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative...